The FDA's decision to appoint Vinay Prasad, MD, MPH, to head its Center for Biologics Evaluation and Research (CBER) raised ...

PI's new objective focusing stage excels in fast nano-focusing applications, such as DNA sequencing, laser-technology, wafer metrology, super-resolution microscopy, medical technology, and slide ...

A Pennsylvania drug developer is investing in a 436-unit multifamily property in Houston in hopes of diversifying its revenue ...

While updated study results confirmed the drug lowers a target protein, the therapy's effect on clinical outcomes was less ...

Qure advances its Huntington’s program toward accelerated approval as PTC Therapeutics reports strong Phase 2 results. Learn ...

Shares of Recursion Pharmaceuticals fell after the company reported a first-quarter loss. Shares slid 13.4% to $4.94 during Monday's trading, and the stock is down 27% year to date.

PI, a global leader in precision motion control and nanopositioning, announces fast delivery of its nanometer-precise, ...

Q1 2025 Earnings Call Transcript May 6, 2025 Evotec SE beats earnings expectations. Reported EPS is $-0.05152, expectations ...

Martin Lyons; Chairman of the Board, President, Chief Executive Officer; Ameren Corp Michael Moehn; Chief Financial Officer, Executive Vice President; Ameren Corp I would now like to turn the ...

Group revenues of € 200 m, on track towards guidance; Shared R&D with similar trend as 2024; Just - Evotec Biologics with continuing growth momentumStrong progress in strategic protein degradation par ...

Shares of ImmunityBio touched a 52-week low after the company received a refusal-to-file letter from the Food and Drug Administration for a supplemental biologics license application for ...